Evidence map›Paper›PMID 41918881›Full record

ArticleFrontiers in cellular neuroscience2026

Altered lipid peroxidation, perineuronal net and oligodendrocyte markers in the frontal cortex of a dual-hit neurodevelopmental model support its relevance to schizophrenia.

Victoria Esuaikoh, Sarah Ibegbulam, Alistair Cook, Bianca McFarland, Nora Nunnington, Ambalangoda Perera, Jingjing Feng, Jennifer A Cale, Madeleine V King

Abstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Victoria EsuaikohMIND Laboratory for Preclinical Research into Mental Illness and Neurodivergence, Division of Physiology Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Sarah IbegbulamMIND Laboratory for Preclinical Research into Mental Illness and Neurodivergence, Division of Physiology Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Alistair CookMIND Laboratory for Preclinical Research into Mental Illness and Neurodivergence, Division of Physiology Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Bianca McFarlandMIND Laboratory for Preclinical Research into Mental Illness and Neurodivergence, Division of Physiology Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Nora NunningtonMIND Laboratory for Preclinical Research into Mental Illness and Neurodivergence, Division of Physiology Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Ambalangoda PereraMIND Laboratory for Preclinical Research into Mental Illness and Neurodivergence, Division of Physiology Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Jingjing FengMIND Laboratory for Preclinical Research into Mental Illness and Neurodivergence, Division of Physiology Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Jennifer A CaleMIND Laboratory for Preclinical Research into Mental Illness and Neurodivergence, Division of Physiology Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.
Madeleine V KingMIND Laboratory for Preclinical Research into Mental Illness and Neurodivergence, Division of Physiology Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The pathogenesis of schizophrenia begins in early neurodevelopment and leads to an array of frontal cortical deficits. They include redox dysregulation, white matter perturbation, loss of perineuronal nets (PNNs) and reduced synaptic density. It is therefore highly desirable that preclinical models used to understand disease, select drug targets and evaluate novel therapeutics encompass similar changes. One approach to improved preclinical modeling incorporates dual-hit neurodevelopmental interventions, like neonatal administration of phencyclidine (PCP, to disrupt development of glutamatergic circuitry) then post-weaning isolation (Iso, to mimic adolescent social stress). We recently showed that rats exposed to PCP-Iso develop GABAergic and inflammatory changes in the frontal cortex, and the current study expands on this by comparing changes to additional cellular and extracellular matrix markers relevant to oxidative stress, myelination, PNN integrity and synaptic vesicle density. Methods: The study used tissue from a previously described cohort of male Lister-hooded rats. They received saline vehicle (Veh, 1 ml/kg s.c.) or PCP (10 mg/kg s.c) on postnatal days (PND) 7, 9 and 11 then were housed in social groups (Gr, 3-4/cage) or post-weaning isolation from PND 21 onwards. Declarative memory was assessed in adulthood (PND 57-80) using a novel object discrimination (NOD) test. Frontal cortical samples were obtained on PND 79-80 and used for immunohistochemical or lectin binding examinations of the lipid peroxidation product 4-hydroxynonenal (4-HNE), oligodendrocyte-associated protein 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase), PNNs and synaptic vesicle glycoprotein 2A (SV2A) throughout the orbitofrontal, prelimbic and infralimbic cortices. In each case data from dual-hit PCP-Iso and single-hit Veh-Iso were compared to each other, and to data from Veh-Gr controls. Results: Single-hit isolation-reared and dual-hit PCP-Iso both showed impaired declarative memory. They also both exhibited reduced PNN density in the orbitofrontal cortex and reduced PNN thickness in the prelimbic/infralimbic cortex. However, PCP-Iso showed additional PNN thinning, 4-HNE upregulation and CNPase downregulation in orbitofrontal regions. Discussion: These findings enhance the face validity of PCP-Iso and support wider use of this preclinical model for evaluating novel therapeutics designed to support parvalbumin-positive neurons and PNNs, promote myelination or normalize redox dysregulation. Unaltered SV2A expression in young adult PCP-Iso mirrors recent dorsolateral prefrontal cortical findings in first-episode psychosis, supports expectations that increased microglial activation precedes aberrant synaptic pruning, and justifies further examinations of synaptic markers in PCP-Iso at later developmental stages.

Indexed as

frontal cortexisolation rearingneonatal PCPoligodendrocyteoxidative stressperineuronal netschizophreniasynaptic density

Identifiers

PMID41918881
PMCPMC13033504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.